LIA Stock Overview
A medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
LivaNova PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$48.20 |
| 52 Week High | US$59.00 |
| 52 Week Low | US$39.00 |
| Beta | 1.01 |
| 11 Month Change | -0.82% |
| 3 Month Change | 18.72% |
| 1 Year Change | 21.11% |
| 33 Year Change | -35.73% |
| 5 Year Change | -37.40% |
| Change since IPO | 178.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| LIA | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.8% | -1.0% | -0.02% |
| 1Y | 21.1% | -7.3% | 8.2% |
Return vs Industry: LIA exceeded the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: LIA exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| LIA volatility | |
|---|---|
| LIA Average Weekly Movement | 6.5% |
| Medical Equipment Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LIA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LIA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 2,900 | Vladimir Makatsaria | www.livanova.com |
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
LivaNova PLC Fundamentals Summary
| LIA fundamental statistics | |
|---|---|
| Market cap | €2.70b |
| Earnings (TTM) | €22.74m |
| Revenue (TTM) | €1.19b |
117.7x
P/E Ratio2.2x
P/S RatioIs LIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIA income statement (TTM) | |
|---|---|
| Revenue | US$1.24b |
| Cost of Revenue | US$396.25m |
| Gross Profit | US$845.49m |
| Other Expenses | US$821.80m |
| Earnings | US$23.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.44 |
| Gross Margin | 68.09% |
| Net Profit Margin | 1.91% |
| Debt/Equity Ratio | 47.8% |
How did LIA perform over the long term?
See historical performance and comparison